Impaired motor activity in a CRISPR SCA5 L253P knock-in mouse is associated with selective β-III-spectrin subcellular redistribution in the cerebellum
Preprint
Abstract
The spinocerebellar ataxia type 5 (SCA5) L253P mutation in β-III-spectrin causes high-affinity actin binding. Here we developed a CRISPR knock-in mouse to determine the i n vivo impact of L253P on Purkinje neurons and motor activity, and to establish a model for future testing of SCA5 therapeutics. Significantly, the knock-in mouse shows impaired motor activity on elevated beam assays at 20 weeks. In the cerebellum, L253P causes a subcellular redistribution of β-III-spectrin in Purkinje neurons. This is marked by loss of β-III-spectrin in distal dendrites, accumulation of β-III-spectrin at the plasma membrane of the soma and proximal dendrites, and formation of inclusions in the soma. The inclusions additionally contain F-actin and α-II-spectrin, accumulate around the nucleus, form at an early age, and are larger in homozygous β-III-spectrin L253P/L253P compared to heterozygous β-III-spectrin L253P/+ mice. In contrast, neurons of the hippocampus and cerebral cortex, where β-III-spectrin is also known to be expressed, abnormally accumulate β-III-spectrin at the plasma membrane but do not form inclusions. To gain greater insight into disease mechanisms, unbiased proteomics identified over 150 cerebellar proteins that physically associate with β-III-spectrin. Of these, cluster analysis revealed a group of 41 proteins, including glutamate receptors, SERCA2, and CaMKII, linked to synaptic transmission. Thus, the effect of the L253P to alter β-III-spectrin localization, including decreased levels in distal dendrites, is likely associated with a disruption of β-III-spectrin function in postsynaptic signaling. Consistent with this, and in agreement with prior findings in knockout mice, the L253P β-III-spectrin knock-in mouse here shows that CaMKII, a calcium sensor and key mediator of glutamate signaling, is ~2-fold activated. Further, the abundance of EAAT4, a glutamate transporter, is significantly reduced. The L253P knock-in mouse primes future preclinical testing of SCA5 therapeutics, such as small molecule modulators of spectrin-actin binding, and glutamate and calcium signaling pathways.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (1R35NS127248-01)
- National Institute of Neurological Disorders and Stroke (R61NS11075)
- National Institute of Neurological Disorders and Stroke (R33NS11075)
- National Institute of Neurological Disorders and Stroke (2R15NS116511-02)
This publication has 36 references indexed in Scilit:
- Molecular consequences of SCA5 mutations in the spectrin-repeat domains of β-III-spectrinJournal of Biological Chemistry, 2025
- Structural basis for high-affinity actin binding revealed by a β-III-spectrin SCA5 missense mutationNature Communications, 2017
- Dominant Mutations in GRM1 Cause Spinocerebellar Ataxia Type 44The American Journal of Human Genetics, 2017
- Progressive SCAR14 with unclear speech, developmental delay, tremor, and behavioral problems caused by a homozygous deletion of the SPTBN2 pleckstrin homology domainAmerican Journal of Medical Genetics Part A, 2017
- Autosomal dominant SCA5 and autosomal recessive infantile SCA are allelic conditions resulting from SPTBN2 mutationsEuropean Journal of Human Genetics, 2013
- Spectrin mutations cause spinocerebellar ataxia type 5Nature Genetics, 2006
- Spinocerebellar Ataxia Type 14 Caused by a Mutation in Protein Kinase C γArchives of Neurology, 2003
- Modulation of the neuronal glutamate transporter EAAT4 by two interacting proteinsNature, 2001
- Characterization of a new β-spectrin gene which is predominantly expressed in brainMolecular Brain Research, 1998
- Spinocerebellar ataxia type 5 in a family descended from the grandparents of President Lincoln maps to chromosome 11Nature Genetics, 1994